There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC) and Autolus Therapeutics (AUTL) with bullish sentiments.
Revance Therapeutics (RVNC)
William Blair analyst Tim Lugo maintained a Buy rating on Revance Therapeutics on May 19. The company’s shares closed last Friday at $20.72.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of 10.6% and a 46.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $32.25, which is a 53.9% upside from current levels. In a report issued on May 4, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Autolus Therapeutics (AUTL)
In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Autolus Therapeutics. The company’s shares closed last Friday at $11.44.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of 5.4% and a 47.9% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Aileron Therapeutics, Kezar Life Sciences, and Portola Pharma.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.25, which is a 77.5% upside from current levels. In a report issued on May 7, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
